Neurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability, and efficacy of NTI164 in Autism Spectrum Disorder (ASD) patients.
Neurotech International (ASX:NTI) has released promising results from a Phase I/II clinical study of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).
A medical dilemma in its own right – the modern treatment of the condition commonly known as ‘autism’ can come at a high cost and with debilitating side effects – something ASX-listed Neurotech International aims to change.
The company recently reported significant development in the preclinical research of its lead asset program, NTI164 – a proprietary cannabis strain that contains high levels of unique minor cannabinoids and less than 0.3% THC, exclusively licensed from Dolce Cann Global.
Neurotech International (ASX:NTI) has today reported significant development in the preclinical research of its lead asset program, NTI164.
The Phase I/II clinical trial announced today is a groundbreaking study where medicinal cannabis containing little to no THC is being tested on autistic children.